期刊
ORPHANET JOURNAL OF RARE DISEASES
卷 16, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13023-021-01722-7
关键词
Hypophosphatasia; Pediatric; Rare bone disease; Alkaline phosphatase; Behavior; Sleep disturbance; Attention deficit hyperactivity disorder; Quality of life
资金
- Alexion Pharmaceuticals [CON73944]
- National Institutes of Health's National Center for Advancing Translational Sciences [KL2TR002492, UL1TR002494]
Children with HPP are at increased risk for ADHD symptoms and other behavioral health challenges, which are often under-recognized in clinical practice. Approximately 67% of children with HPP exhibit clinically significant behavioral health challenges, such as sleep disturbance and symptoms of ADHD, which are associated with reduced physical and psychosocial quality of life. Despite age-typical development of adaptive skills in most children, emotional and behavioral challenges are linked to weaker adaptive function.
BackgroundHypophosphatasia (HPP) is a rare genetic disorder caused by loss-of-function mutations in the ALPL gene encoding tissue nonspecific alkaline phosphatase. It is characterized by defective bone mineralization associated with low alkaline phosphatase activity. Clinical features of pediatric HPP are highly variable, and can include premature loss of teeth, musculoskeletal problems, and impaired mobility. The effects of pediatric HPP on sleep, mood, regulation of attention and behavior, and other aspects of behavioral health have not been comprehensively studied.MethodsParents of 30 children with HPP (14 females, 16 males) between the ages of 3 and 16 years (mean age=8.0 years) enrolled in this cross-sectional survey-based study. Molecular genetic and biochemical testing as well as clinical records were reviewed to verify diagnosis of HPP. The cohort included 15 patients with a more clinically severe presentation of HPP who had received treatment with enzyme replacement therapy (asfotase alfa) and 15 children with less severe HPP who were treatment-naive. Parents provided information regarding psychopathological comorbidity, emotional and behavioral well-being, and quality of life.ResultsClinically significant behavioral health challenges were evident in 67% of children with HPP. The most common behavioral findings included sleep disturbance and symptoms of attention deficit hyperactivity disorder (ADHD), each of which were observed >= 50% of individuals. Sleep disturbance, pain interference, poor behavioral regulation, and mood/anxiety symptoms were associated with reduced physical and psychosocial quality of life. Behavioral concerns were evident among children with HPP receiving asfotase alfa treatment as well as among children with clinically less severe disease who had not initiated therapy. Although most children in the cohort (77%) had age-typical development of adaptive skills, emotional and behavioral challenges were associated with weaker adaptive function.ConclusionsChildren with HPP are at increased risk for ADHD symptoms and other behavioral health challenges. There is likely an under-recognition of these findings in clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据